drugset / Trial / NCT00004815

Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome

NCT00004815

Non-randomizedTreatment

Summary

OBJECTIVES: I. Assess the safety and efficacy of recombinant human insulin-like growth factor 1 in a patient with Werner's syndrome and osteoporosis.

Timeline

Start
1992-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic Subcutaneous

Indications